Chelation Therapy Products - Insulin Glargine Recombinant Interaction Details

Interaction Details

Insulin Glargine Recombinant is classified as belonging to the following category: Insulin

Ethylenediamine tetraacetic acid (EDTA) can decrease the activity of insulin and increase the risk for hypoglycemia.
Concomitant use of disodium EDTA with insulin can cause severe decreases in blood glucose concentrations. Additionally, EDTA chelates zinc in insulin products and might interfere with the onset and duration of activity of various insulin preparations.

Interaction Rating

Major

Likelihood of Occurrence

Probable

Interaction has not been documented in well-controlled studies, however, the interaction has been demonstrated in some small human studies or in controlled animal studies in conjunction with multiple case reports.

References

McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
Grier MT, Meyers DG. So much writing, so little science: a review of 37 years literature on edetate sodium chelation therapy. Ann Pharmacother 1993;27:1504-9.
Lacy CF, Armstrong LL, Ingrim NB, et al. Drug Information Handbook. 6th ed. Hudson, OH:Lexi-Comp Inc 1998:439-41.

Chelation Therapy Products - More Interactions

Chelation Therapy Products interacts with 90 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.

Major	The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur.
Moderate	Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur.
Minor	Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction.
Unknown	No interactions have been reported or no interaction data is currently available.